ArticleBritish journal of cancer2004
Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage.
Article in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature.Journal of neuro-oncology · 2010Pooled it
- Preoperative prediction of p53 overexpression in pituitary neuroendocrine tumors using MRI radiomics.Frontiers in neurology · 2025Article
- p53/Cancers · 2023Article
- Spontaneous expression of the gene ofVeterinary world · 2022Article
- p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2022Article
- Targeted contrast agents and activatable probes for photoacoustic imaging of cancer.Chemical Society reviews · 2022Review
- Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance.Communications biology · 2021Article
- Article
- The Progressive Mutagenic Effects of Acidic Bile Refluxate in Hypopharyngeal Squamous Cell Carcinogenesis: New Insights.Cancers · 2020Article
- p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.Cellular oncology (Dordrecht, Netherlands) · 2018Article
- Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report.Cellular oncology (Dordrecht, Netherlands) · 2018Article
- The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.Journal of neuro-oncology · 2018Article
- Scaffold Proteins in Gastrointestinal Tumors as a Shortcut to Oncoprotein Activation.Gastrointestinal tumors · 2017Review
- TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas.Journal of neuro-oncology · 2014Article
- Expression of p53, epidermal growth factor receptor, Ki-67 and OOncology letters · 2013Article
- Diagnostic segregation of human brain tumours using Fourier-transform infrared and/or Raman spectroscopy coupled with discriminant analysis.Analytical methods : advancing methods and applications · 2012Article
- Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.Journal of neuro-oncology · 2012Article
- Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy.International journal of oncology · 2009Article
- The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas.Neoplasia (New York, N.Y.) · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 2 countries.
Funding
Abstract
Abnormalities of the p53 tumor-suppressor gene are found in a significant proportion of astrocytic brain tumours. We studied tumour specimens from 74 patients evaluated over 20 years at the Massachusetts General Hospital, where clinical outcome could be determined and sufficient pathologic material was available for immunostaining. p53 expression studies employed an affinity-purified p53 monoclonal antibody, whose specificity was verified in absorption studies and, in a minority of cases, a second antibody recognising a different epitope of p53. Significant overexpression of p53 protein was found in 48% of the 74 tumours included in this series and high levels of expression were associated with higher mortality from astrocytic tumours (P<0.001, log rank). Multivariate analyses revealed that immunohistochemically detected p53 was an independent marker of shortened progression-free and overall actuarial survival in patients with astrocytic tumours, suggesting that increased expression of p53 plays an important role in the pathobiology of these tumours. In a subset of 36 cases, coding regions of the p53 gene were completely sequenced via SSCP and direct DNA sequencing, revealing that overexpression of p53 protein is not always associated with point mutations in conserved exons of the p53 gene. Finally, we confirmed p53 protein expression in early-passage human glioma cell lines of known p53 mutational status and immunostaining scores. Although grade continues to be the strongest prognostic variable, the use of p53 staining as a prognostic indicator, in contrast to mutational DNA analyses, may be a useful adjunct in identifying patients at higher risk of treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.